About Us  |  Our History

Building on 40 Years of Medical Innovation

For over four decades, Theragenics has been dedicated to improving the lives of patients through the development and production of life-saving radioisotopes. Our journey began in 1981 when a group of physicists from Georgia Institute of Technology set out to create innovative radiological pharmaceuticals and devices to combat cancer.

Our deep-rooted expertise in radioisotope production has enabled us to develop a strong foundation in cancer care. While we have expanded our offerings to include other medical technologies, our commitment to providing critical radioisotopes remains unwavering. These vital components are essential for a wide range of cancer treatments, and we are proud to play a significant role in improving patient outcomes.

Brachytherapy

Interventional
Radiology

Interventional
Cardiology

Vascular
Surgery

Theragenics Timeline

2020s

Operations expand to offer contract manufacturing services to support radiopharmaceutical production and delivery.

Theragenics celebrates our 40th anniversary, and we continue to build on our rich history of advancing patient care.

2010s

Theragenics acquires multiple brachytherapy suppliers, expanding market access.

AgX100® receives FDA 510(k) clearance.

Juniper Investment Company acquires Theragenics and takes the organization private. Our company continues to build on its foundation as a leading medical device company.

Theragenics acquires Arrotekâ„¢ Medical, a full-service medical device design consultancy, expanding operations into Sligo, Ireland.

2000s

Theragenics launches TheraSeed® direct to customers.

Product line expands with the acquisition of an existing Iodine-125 prostate business. This purchase enables Theragenics to supply both Palladium-103 and Iodine-125 seeds.

Theragenics initiates mergers and acquisitions to diversity into other markets, including interventional radiology and cardiology, specialty needles, and surgical products.

1990s

First cyclotron becomes operational in our Georgia facility.

TheraSeed® receives CE Marking, which allows Theragenics to market the device throughout Europe.

Our state-of-the-art Buford manufacturing facility officially opens with 14 cyclotrons.

1980s

Theragenics is founded in 1981 as Nuclear Medicine, Inc. by a group of physicists at the Georgia Institute of Technology, with an initial focus to develop radiological devices to treat cancer.

TheraSeed®, a Palladium-103 based brachytherapy treatment, receives 510K clearance from the FDA.

The first patient is treated with TheraSeed®

134,000 sq ft

Radioisotope production facility in Buford, GA

14 high-powered cyclotrons

For commercial-scale radioisotope manufacturing

52,000 Sq ft

State-of-the-art design facility in Sligo, Ireland

40+ Countries

Shipping product to 40+ countries

271,000 +

Patients treated with our brachytherapy seeds

21M +

Brachytherapy seeds supplied to date

;

About Us

We design and deliver innovative solutions that consistently improve patient outcomes.

More About Us
;

Careers

Ready to join a dynamic team committed to advancing medical device innovation?

view open positions

Contact Us

Get in touch to learn more about our products and services.

Speak with an Expert